Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01546389 · ClinicalTrials.gov registry record · Phase 1
Sanaria™ PfSPZ Challenge Vaccine
A Phase 1 study of Malaria, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01546389 is a Phase 1 study of Malaria that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 30 participants, below the 257-participant average among 27 other Malaria trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01546389, a Phase 1 study of Malaria, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will randomize 30 healthy adult participants to one of three cohorts comprised of six groups of 5 individuals per group to simultaneously receive PfSPZ Challenge via the ID route. The goal will be to determine the optimal dose required to achieve 100% infectivity (ID100) of adult volunteers with P. falciparum malaria.
Conditions Studied
Interventions
- BIOLOGICAL Sanaria™ PfSPZ Vaccine
- DRUG Chloroquine
Study Locations (1)
Maryland
- University of Maryland School of Medicine - Center for Vaccine Development - Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01546389
The ClinicalTrials.gov registry entry for NCT01546389 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 27 other Malaria trials with a reported enrollment target (88% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 2 interventions - of which Sanaria™ PfSPZ Vaccine is the first listed.
NCT01546389 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01546389 about?
NCT01546389 is a clinical study titled "Sanaria™ PfSPZ Challenge Vaccine". This study will randomize 30 healthy adult participants to one of three cohorts comprised of six groups of 5 individuals per group to simultaneously receive PfSPZ Challenge via the ID route. The goal will be to determine the optimal dose required to achieve 100% infectivity (ID100) of adult voluntee...
What is the current status of trial NCT01546389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-04. Estimated completion is 2013-04.
What conditions does trial NCT01546389 study?
This clinical trial studies the following conditions: Malaria.
What interventions are being tested in trial NCT01546389?
The interventions under investigation include: Sanaria™ PfSPZ Vaccine (BIOLOGICAL), Chloroquine (DRUG).
Who is sponsoring clinical trial NCT01546389?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01546389 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral E1018 in Healthy Adult Participants
RECRUITING · Phase 1
-
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
RECRUITING · Phase 1
-
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
ACTIVE NOT RECRUITING · Phase 1
-
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Evaluate CIS43LS in Healthy Adults
COMPLETED · Phase 1
-
Blood-Stage Plasmodium Vivax Cell Bank
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.